Merck KGaA Sign an Exclusive Worldwide License Agreement with Debiopharm for Xevinapant

 Merck KGaA Sign an Exclusive Worldwide License Agreement with Debiopharm for Xevinapant

Merck KGaA Sign an Exclusive Worldwide License Agreement with Debiopharm for Xevinapant

Shots:

  • Debiopharm to receive $226M up front, ~$853.7M as regulatory and commercial milestones along with royalties. The transaction is expected to close in early Q2’21
  • Merck KGaA get an exclusive right to develop and commercialize xevinapant globally, including in the US and will co-fund the ongoing P-III TrilynX study that involves assessing Xevinapant vs PBO in 700 patients in combination with CRT in cisplatin-eligible patients with high-risk LA SCCHN
  • Xevinapant has received the FDA’s BTD in Feb 2020, based on the P- II results that showed xevinapant + CT reduced risk of death by 51% vs SOC in this patient with high-risk LA SCCHN

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Pinterest

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post